Literature DB >> 15823444

Endoscopic treatments for obesity: past, present and future.

Christopher J Gostout1, Elizabeth Rajan.   

Abstract

Obesity is recognized as a serious, chronic illness affecting all ages. The cause for obesity is multi-factorial, which makes successful management complex and challenging. Meaningful weight loss is frequently difficult to achieve, particularly when the goal is not merely to lose weight but to maintain this loss. The efficacy of future endoscopic approaches needs to be validated through well-designed controlled studies, and verification of safety is essential. Endoluminal therapies must have a sound physiologic basis for their development. The availability of specialized radionuclide imaging of gastric capacity and accommodation provide a useful tool in constructing interventions. Endotherapy is likely best suited for nonmorbid obese individuals with BMI ranging from 30 to 39 or as a budge to bariatric surgery. This specific BMI range has been targeted by the National Institutes of Health for emerging technologies. Presurgical weight loss to reduce surgical risk is another potential target group. Regardless of which endoscopic methods prevail, patients will continue to require a comprehensive, multi-modality management approach to this complex disease.

Entities:  

Mesh:

Year:  2005        PMID: 15823444     DOI: 10.1016/j.gtc.2004.12.001

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  9 in total

1.  Acute technical feasibility of an endoscopic duodenal-jejunal bypass sleeve in a porcine model: a potentially novel treatment for obesity and type 2 diabetes.

Authors:  M Tarnoff; S Shikora; A Lembo
Journal:  Surg Endosc       Date:  2008-02-13       Impact factor: 4.584

2.  A case of asymptomatic fungal and bacterial colonization of an intragastric balloon.

Authors:  Halil Coskun; Suleyman Bozkurt
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

3.  Gastrointestinal issues in the assessment and management of the obese patient.

Authors:  Zulfiqar Hussain; Eamonn M M Quigley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-07

4.  Intragastric balloon insertion increases the frequency of erosive esophagitis in obese patients.

Authors:  Angelo Rossi; Gianluca Bersani; Giorgio Ricci; Chiara Petrini; Giovanni DeFabritiis; Vittorio Alvisi
Journal:  Obes Surg       Date:  2007-10       Impact factor: 4.129

5.  Chronic in-vivo experience with an endoscopically delivered and retrieved duodenal-jejunal bypass sleeve in a porcine model.

Authors:  M Tarnoff; S Shikora; A Lembo; K Gersin
Journal:  Surg Endosc       Date:  2007-11-20       Impact factor: 4.584

6.  BioEnterics intragastric balloon: clinical outcomes of the first 100 patients--a Turkish experience.

Authors:  Halil Coskun; Ozgur Bostanci; Ece Dilege; Alp Bozbora
Journal:  Obes Surg       Date:  2008-06-03       Impact factor: 4.129

7.  The feasibility of delivering a duodenal-jejunal bypass liner (EndoBarrier) endoscopically with patients under conscious sedation.

Authors:  Parviez Koehestanie; Bark Betzel; Kemal Dogan; Frits Berends; Ignace Janssen; Edo Aarts; Marcel Groenen; Peter Wahab
Journal:  Surg Endosc       Date:  2013-08-27       Impact factor: 4.584

8.  Short-term outcomes of the new intragastric balloon End-Ball® for treatment of obesity.

Authors:  Marek Buzga; Tomas Kupka; Milan Siroky; Habib Narwan; Evzen Machytka; Pavol Holeczy; Zdeněk Švagera
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2016-11-29       Impact factor: 1.195

9.  Intragastric Balloon for Overweight Patients.

Authors:  Flavio Augusto Martins Fernandes; Gustavo L Carvalho; Diego L Lima; Prashanth Rao; Phillip P Shadduck; Isabelle D Montandon; Juscielle de Souza Barros; Ingrid Lais Vieira Rodrigues
Journal:  JSLS       Date:  2016 Jan-Mar       Impact factor: 2.172

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.